PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer|Locally Advanced Breast Cancer|Recurrent Breast Cancer|Metastatic Breast Cancer|ER+ Breast Cancer|HER2-positive Breast Cancer
Interventions: DRUG: Palbociclib|DRUG: Avelumab
Sponsor: Royal Marsden NHS Foundation Trust
Collaborators: Pfizer|Breast Cancer Now